SARS-CoV-2 Mutations and their Viral Variants

dc.contributor.authorCosar, Begum
dc.contributor.authorKaragulleoglu, Zeynep Yagmur
dc.contributor.authorUnal, Sinan
dc.contributor.authorInce, Ahmet Turan
dc.contributor.authorUncuoglu, Dilruba Beyza
dc.contributor.authorTuncer, Gizem
dc.contributor.authorKilinc, Bugrahan Regaip
dc.contributor.authorOzkan, Yunus Emre
dc.contributor.authorOzkoc, Hikmet Ceyda
dc.contributor.authorDemir, Ibrahim Naki
dc.contributor.authorEker, Ali
dc.contributor.authorKaragoz, Feyzanur
dc.contributor.authorSimsek, Said Yasin
dc.contributor.authorYasar, Bunyamin
dc.contributor.authorPala, Mehmetcan
dc.contributor.authorDemir, Aysegul
dc.contributor.authorAtak, Irem Naz
dc.contributor.authorMendi, Aysegul Hanife
dc.contributor.authorBengi, Vehdi Umut
dc.contributor.authorSevel, Guldane Cengiz
dc.contributor.authorAltuntas, Evrim Gunes
dc.contributor.authorKilic, Pelin
dc.contributor.authorDemir-Dora, Devrim
dc.contributor.orcIDhttps://orcid.org/0000-0003-0359-6308en_US
dc.contributor.pubmedID34580015en_US
dc.date.accessioned2022-11-28T12:14:16Z
dc.date.available2022-11-28T12:14:16Z
dc.date.issued2022
dc.description.abstractMutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occur spontaneously during replication. Thousands of mutations have accumulated and continue to since the emergence of the virus. As novel mutations continue appearing at the scene, naturally, new variants are increasingly observed.Since the first occurrence of the SARS-CoV-2 infection, a wide variety of drug compounds affecting the binding sites of the virus have begun to be studied. As the drug and vaccine trials are continuing, it is of utmost importance to take into consideration the SARS-CoV-2 mutations and their respective frequencies since these data could lead the way to multi-drug combinations. The lack of effective therapeutic and preventive strategies against human coronaviruses (hCoVs) necessitates research that is of interest to the clinical applications.The reason why the mutations in glycoprotein S lead to vaccine escape is related to the location of the mutation and the affinity of the protein. At the same time, it can be said that variations should occur in areas such as the receptor-binding domain (RBD), and vaccines and antiviral drugs should be formulated by targeting more than one viral protein.en_US
dc.identifier.issn1359-6101en_US
dc.identifier.scopus2-s2.0-85115962112en_US
dc.identifier.urihttps://reader.elsevier.com/reader/sd/pii/S1359610121000538?token=C9FBD1A54298E3BCC768B8B13389FF5F03C112337F6267D07FEAD7ADC6B368F6CF923C62B964FCC4BF715F86E2582181&originRegion=eu-west-1&originCreation=20221128121000
dc.identifier.urihttp://hdl.handle.net/11727/8167
dc.identifier.wos000767550600002en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.cytogfr.2021.06.001en_US
dc.relation.journalCYTOKINE & GROWTH FACTOR REVIEWSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectMutationen_US
dc.subjectReceptor-binding domainen_US
dc.subjectSARS-CoV-2en_US
dc.subjectSpike proteinen_US
dc.subjectViral variantsen_US
dc.titleSARS-CoV-2 Mutations and their Viral Variantsen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
68.pdf
Size:
2.93 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: